Intense Airway Eosinophilia in Asthma

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

918 participants

Study Classification

OBSERVATIONAL

Study Start Date

2017-06-06

Study Completion Date

2018-08-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In asthma, the type and importance of the inflammatory response in the airways has allows identification of different phenotypes. Of these, one of the most common is eosinophilic asthma, based on induced sputum differential cell count. Patients with severe asthma and an eosinophilic asthma phenotype have different pathophysiological characteristics than those seen in patients with with mild asthma. However, few studies have compared patients with eosinophilic phenotype according to the severity of asthma. In addition, the stability of the phenotype based on the sputum results has been criticized.

This study aims to describe the characteristics of patients with eosinophilic asthma phenotype according to the severity of asthma and determine the stability of the phenotype.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Follow-up of Mild Eosinophilic Asthma

NCT04650503

Asthma

UNKNOWN

Diagnostic and Translational Values of Point-of-care Blood Eosinophils and Exhaled Nitric Oxide (FeNO) in People Referred by Primary Care for Suspected Asthma

NCT05992519

Asthma Asthma in Children Diagnosis +1 more

COMPLETED

Diagnosing Asthma With Clinically Accessible, Non-invasive, and Efficient Tests: a Child-inclusive Translational Investigation

NCT07011394

Diagnosis Inflammation Asthma in Children +1 more

RECRUITING

Phenotypic and Functional Characterization of Neutrophils and Eosinophils in Severe Asthma Treated With Biotherapy

NCT05972213

Asthma

RECRUITING

Airway Inflammation and Disease Burden in Asthmatic Smokers

NCT02833727

Asthma

UNKNOWN

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Characteristics of asthmatic subjects with sputum eosinophilia will be compared according to asthma severity.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Asthma Eosinophilic Asthma

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

RETROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Eosinophilic

Asthmatic patients showing 3% or more sputum eosinophils

No interventions assigned to this group

Non-eosinophilic

Asthmatic patients showing less than 3% sputum eosinophils

No interventions assigned to this group

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Aged 18 years and over
* With a proven diagnosis of asthma as defined by one of the above criteria of current guidelines (36):

1. Forced expiratory volume in one second (FEV1) increase by at least 12% (and ≥200 ml) after administration of a bronchodilator
2. Current asthma symptoms and a methacholine provocative concentration inducing a 20% fall in FEV1 (PC20) \<16 mg/ml
3. A respirologist's current diagnosis of asthma found in the patient's medical report 3. Non-smokers or smokers/ex-smokers defined as someone with a smoking history \<10 pack-years 4. With sputum differential cell count result 5. Considered to receive optimal treatment for their disease (as per current guidelines except for patients included in exploratory objective 1.

6\. Stable asthma and asthma medication for at least 4 weeks before data analysis 7. Written informed consent obtained for inclusion in the database

Exclusion Criteria

1. Any respiratory disease apart from asthma
2. Current or ex-smokers should not have a smoking history ≥10 pack-year before data analysis. Patients who administer nicotine in other forms (patches, chew tobacco, e-cigarette, etc.) will be excluded
3. Unstable asthma medication \<4 weeks before data analysis
4. Asthma exacerbation (see definition below) \<4 weeks before data analysis
5. Respiratory tract infection \<4 weeks before data analysis

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No